Form 4: Corcept Therapeutics Officer Exercises Options and Sells Shares Under 10b5-1 Plan

Joseph Douglas Lyon, Chief Accounting & Technology Officer at Corcept Therapeutics Inc., executed planned stock option exercises and subsequent share sales.

Summary

• Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics Inc. (CORT), engaged in stock transactions on July 17 and July 18, 2025.
• On July 17, 2025, Lyon exercised options to acquire 3,877 shares of common stock at an exercise price of $13.56 per share.
• Immediately following, on July 17, 2025, Lyon sold 3,877 shares of common stock at a weighted average price of $73.4753 per share, with actual sale prices ranging from $73.40 to $73.74.
• On July 18, 2025, Lyon exercised options to acquire an additional 200 shares of common stock at an exercise price of $13.56 per share.
• Concurrently, on July 18, 2025, Lyon sold 200 shares of common stock at a price of $73.40 per share.
• All sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on August 30, 2024.
• Following these transactions, Lyon beneficially owns 10,066 shares of common stock directly, which includes 1,552 shares underlying unvested restricted stock awards.
• Lyon also holds 37,394 stock options with an exercise price of $13.56, expiring on February 7, 2030.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive from the perspective of the insider, who realized significant gains from option exercises and sales. For the company, it's neutral as it's a routine insider transaction under a 10b5-1 plan, indicating planned activity rather than a sudden loss of confidence.

Positives

• The officer realized a significant profit by exercising options at $13.56 and selling shares at prices ranging from $73.40 to $73.74.
• The transactions were conducted under a pre-arranged 10b5-1 plan, indicating a planned and transparent approach to insider trading.

Negatives

• The sale of shares by an officer could be perceived as a slight reduction in insider confidence, although it is common for officers to diversify holdings or cover exercise costs.

Risks

• No specific company risks are detailed in this Form 4 filing. The primary risk related to this document type is potential misinterpretation of insider trading activity if not understood as part of a 10b5-1 plan.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing details routine insider transactions (option exercise and sale) and does not provide information relevant to broader industry trends or competitive landscape analysis.

Related Party Transactions

• The document details transactions between an officer and the company's securities, which are inherently related-party transactions in the context of insider trading disclosures. However, it does not disclose other types of related party dealings beyond equity compensation and sales.

Stakeholder Impact

• Shareholders: The sale of shares by an officer, even under a 10b5-1 plan, might be viewed by some as a slight reduction in insider ownership, though it's a common practice for diversification or liquidity.
• Employees: No direct impact on employees is indicated.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Next Steps

• The document does not mention any specific future actions, events, or milestones for the company, beyond the vesting schedule for the reporting person's restricted stock awards.

Key Dates

Recommendation

Keywords

Corcept Therapeutics, CORT, SEC Form 4, Insider Trading, Stock Options, Share Sale, 10b5-1 Plan, Joseph Douglas Lyon, Officer Transaction, Equity Compensation